首页> 外文OA文献 >Analysis of Multimodal Treatment Outcome in Renal Cell Carcinoma Patients with Bone Metastasis
【2h】

Analysis of Multimodal Treatment Outcome in Renal Cell Carcinoma Patients with Bone Metastasis

机译:肾细胞癌骨转移患者多模式治疗结果分析

摘要

We retrospectively reviewed the treatment outcome of 12 renal cell carcinoma (RCC) patients with bone metastasis who had undergone targeted therapy along with a regimen of multimodal treatment. We performed metastatectomy following nephrectomy on patients with resectable foci. Patients with unresectable bone metastasis underwent radiation therapy. With the exception of two patients, zoledronic acid was also administered. As a result, the overall survival rates of 83.3% at 1 year and 72.9% at 2 years in our study compared favorably with reported cases. Patients with complete resection of solitary bone metastasis with or without extrabone lesions had favorable outcomes. As differences in the response of the targeted therapy can be observed between bone and extrabone metastases, control of bone metastasis may be a key factor for the prognosis of metastatic RCC patients.
机译:我们回顾性地回顾了12例接受靶向治疗以及多模式治疗方案的骨转移性肾细胞癌(RCC)患者的治疗结果。肾切除术后我们对可切除灶的患者进行了转移切除术。患有无法切除的骨转移的患者接受了放射治疗。除两名患者外,还服用唑来膦酸。结果,在我们的研究中,总生存率在1年时为83.3%,在2年时为72.9%,与报告的病例相比是有利的。完全切除孤立骨转移伴或不伴骨外病变的患者均具有良好的预后。由于可以在骨转移与骨外转移之间观察到靶向治疗的反应差异,因此控制骨转移可能是转移性RCC患者预后的关键因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号